Fabhalta (iptacopan) — United Healthcare
Complement 3 glomerulopathy (C3G)
Initial criteria
- Diagnosis of complement 3 glomerulopathy (C3G)
- AND
- Used to reduce proteinuria
Reauthorization criteria
- Documentation of positive clinical response to Fabhalta therapy demonstrated by a reduction in proteinuria
Approval duration
12 months